Viewing data from:

PREVACID NAPRAPAC 250 (COPACKAGED)

NDA

LANSOPRAZOLE; NAPROXEN | N021507 | TAKEDA PHARMACEUTICALS NORTH AMERICA INC

3 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

4 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (3)

Sort:

#002 — 15MG,N/A;N/A,250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RLD

0 patents0 exclusivities▴

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL | Approved: Nov 14, 2003

No patent or exclusivity listings for this strength.

#003 — 15MG,N/A;N/A,375MG

0 patents0 exclusivities▾

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL | Approved: Nov 14, 2003

#004 — 15MG,N/A;N/A,500MG

0 patents0 exclusivities▾

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL | Approved: Nov 14, 2003